ArticleBioMed research international2017
miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.
Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Exploring dysregulated miRNAs in cryptorchidism: a systematic review.The Journal of international medical research · 2021Pooled it
- miRNAs in Glomerular Diseases: From Pathogenic Insight to Therapeutic Potential: A Narrative Review.Cells · 2026Review
- miR-7213-5p-mediated suppression of CCL19 in fibroblast cells may attenuate lupus nephritis.Clinical and experimental medicine · 2025Article
- Emerging roles of non-coding RNAs in idiopathic nephrotic syndrome: a narrative review.BMC nephrology · 2025Review
- What a Modern Physician Should Know About microRNAs in the Diagnosis and Treatment of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- Biochemical analysis of miR-217 and miR-532 in patients with fibromyalgia.European journal of medical research · 2025Article
- MiR-217 Regulates SIRT1 Expression and Promotes Inflammatory and Apoptotic Responses in Osteoarthritis.Genes · 2023Article
- Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies.International journal of molecular sciences · 2023Review
- Epigenetic Mechanisms and Nephrotic Syndrome: A Systematic Review.Biomedicines · 2023Review
- Article
- MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy.Frontiers in pharmacology · 2022Article
- Novel Biomarkers in Membranous Nephropathy.Frontiers in immunology · 2022Review
- Investigating the Molecular Mechanism of Quercetin Protecting against Podocyte Injury to Attenuate Diabetic Nephropathy through Network Pharmacology, MicroarrayData Analysis, and Molecular Docking.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Pathogenic Role of MicroRNA Dysregulation in Podocytopathies.Frontiers in physiology · 2022Review
- Altered expression of serum miR-106a, miR-19b, miR-17, and PTEN in patients with idiopathic membranous nephropathy.Journal of clinical laboratory analysis · 2021Article
- Screening and Analysis of Key Genes in miRNA-mRNA Regulatory Network of Membranous Nephropathy.Journal of healthcare engineering · 2021Article
- WGCNA Analysis Identifies Polycystic Ovary Syndrome-Associated Circular RNAs That Interact with RNA-Binding Proteins and Sponge miRNAs.International journal of general medicine · 2021Article
- MicroRNAs as Biomarkers for Nephrotic Syndrome.International journal of molecular sciences · 2020Review
- Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy.Non-coding RNA research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs have recently been verified as useful diagnostic biomarkers in various diseases. In this study, we investigated whether miR-217 is a useful diagnostic biomarker and the possible pathological mechanism of miR-217 in this disease.
methodsPatients with focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and diabetic nephropathy (DN) and control patients were enrolled in this study. The miR-217 inhibitor and mimics were transfected into human podocyte cells to investigate the pathological mechanism of miR-217 in this disease. Relevant indicators were detected and tested.
resultsCompared with control patients, miR-217 was significantly downregulated and TNFSF11 was significantly upregulated in MN. Then, miR-217 had obvious separation between patients with MN and control patients, with an AUC of 0.941, a cutoff value of <750.0 copies/ul, and sensitivity and specificity of 88.9% and 75.9%. In addition, the TNFSF11 was confirmed to be the target gene of miR-217. Finally, in in vitro experiments, the upregulation of miR-217 could decrease the expression of TNFSF11 and not induce human podocyte cells apoptosis; however, the downregulation of miR-217 could bring about an opposite change.
conclusionsmiR-217 is a useful diagnostic biomarker and is involved in human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.